CASP4 and neoplasm: In support, adenocarcinoma patients who had tumor-associated levels of caspase-4 higher than 377 pg/ml (n = 42/53, 79,3%) survived less (median = 0.925 years) than patients with lower levels (n = 11/53, 20,7%; median survival =3.03 years) (Fig. 2e).